Future Perspectives: Agents on the Horizon.
As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.
Jose R
JR
Maya
Mohammad Ali
MA
Sadiq
Aniruddha
A
Agarwal
Peter K
PK
Kaiser
Glenn L
GL
Stoller
Yasir Jamal
YJ
Sepah
Quan Dong
QD
Nguyen
D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D015195:Drug Design; D055808:Drug Discovery; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008269:Macular Edema / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors